Brooke Story Sells 2,300 Shares of LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Brooke Story sold 2,300 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the transaction, the director directly owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

LivaNova Stock Down 2.2%

Shares of LivaNova stock opened at $78.93 on Thursday. LivaNova PLC has a one year low of $48.82 and a one year high of $85.76. The company has a market cap of $4.35 billion, a P/E ratio of 23.35 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm has a fifty day moving average of $80.56 and a two-hundred day moving average of $73.22.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, analysts forecast that LivaNova PLC will post 3.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on LIVN. Needham & Company LLC boosted their target price on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. KeyCorp raised their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Stifel Nicolaus set a $85.00 price target on LivaNova in a research note on Wednesday, August 5th. Weiss Ratings raised LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Finally, Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.12.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Tidal Investments LLC purchased a new stake in shares of LivaNova during the 2nd quarter worth approximately $204,000. WINTON GROUP Ltd acquired a new stake in shares of LivaNova in the 2nd quarter worth approximately $4,824,000. Integrated Wealth Concepts LLC purchased a new position in LivaNova in the 2nd quarter valued at approximately $119,000. Squarepoint Ops LLC acquired a new position in LivaNova during the second quarter worth $1,418,000. Finally, Allworth Financial LP raised its holdings in LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.